Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19

Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14–20 days. However, about 15% of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the eld...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Vishal, Thakur, Shalini, Rao, Jyothsna, Arakeri, Gururaj, Brennan, Peter A., Jadhav, Sachin, Sayeed, Mufti Suhail, Rao, Gururaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232064/
https://www.ncbi.nlm.nih.gov/pubmed/32425307
http://dx.doi.org/10.1016/j.mehy.2020.109845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232064/
https://www.ncbi.nlm.nih.gov/pubmed/32425307
http://dx.doi.org/10.1016/j.mehy.2020.109845

Ejemplares similares